Pipeline updates are highly awaited events in the
pharma/biotech sector as they play an important role in deciding
whether or not to invest in a particular company. These updates
provide information on experimental drugs and at times give an
insight into the commercial potential of the candidate once it is
successfully developed and commercialized.
Earlier this week,
) announced that it has enrolled the first patient in a
randomized, placebo-controlled phase III study on metadoxine
extended release (MDX) for the treatment of adults suffering from
attention deficit hyperactivity disorder (ADHD). The study is
expected to be completed in the second half of 2014.
Alcobra stated in its press release that MDX is not a stimulant
like several ADHD medicines. According to the company, MDX's
novel mechanism of action does not target dopamine or
ADHD is a childhood disorder that can persist even in adults.
According to the Centers for Disease Control and Prevention
(CDC), approximately 9.5% of the U.S. population aged between 3
years and 17 years are diagnosed with ADHD.
We note that
) holds a strong position in the ADHD market. Shire's Vyvanse is
approved in the U.S. as a maintenance treatment for ADHD in
adults as well as children and adolescents (6 years−17 years).
Other ADHD drugs in Shire's portfolio include Adderall XR,
Intuniv and Equasym.
We expect investor focus to remain on further pipeline updates
Alcobra holds a Zacks Rank #3 (Hold). Other better-ranked stock
in the health care sector include
Lannett Company, Inc.
Questcor Pharmaceuticals, Inc.
), both carrying a Zacks Rank #1 (Strong Buy). Shire also carries
a Zacks Rank #1.
ALCOBRA LTD (ADHD): Get Free Report
LANNETT INC (LCI): Free Stock Analysis Report
QUESTCOR PHARMA (QCOR): Free Stock Analysis
SHIRE PLC-ADR (SHPG): Free Stock Analysis
To read this article on Zacks.com click here.